Devonian Health Group is trading 5.6% higher at CA$7.50 on October 26, 2026, with no new company announcement explaining the move. - The latest company news was Health Canada authorization, announced October 20, for a 150-patient study of a Thykamine formulation to prevent radiation-related skin injury. - Supplied closing prices remained CA$7.10 for several sessions after that update, so it cannot be confirmed as the direct cause of this morning’s rise. - Supplied market indices are modestly higher, but do not establish a broad-market explanation.